Vivodyne, a San Francisco, CA-based company developing drug testing on lab-grown 3D human tissues, raised $40M in Series A funding.
The round was led by Khosla Ventures, with participation from new investors Lingotto Investment Management, Helena Capital, Fortius Ventures, and existing investors Kairos Ventures, CS Ventures, Bison Ventures, and MBX Capital.
The company intends to use the funds to scale its robotics+AI approach and R&D efforts.
Led by COO Julie O’Shaughnessy and CEO Andrei Georgescu, Vivodyne enables large-scale clinical testing on lab-grown human tissues that can recapitulate the complexity of human disease, leading to more accurate results. This enables pharmaceutical companies to leverage these fully functional tissues across the entire preclinical pipeline, from initial target discovery through clinical candidate selection through safety and efficacy testing, improving success rates in human trials.
FinSMEs
29/05/2025